We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of …

emanating from China's economic ascent could in theory either augment or stifle U.S. innovation. Using three decades of U ….S. patents matched to corporate owners, we quantify how foreign competition affects domestic innovation. Rising import exposure … sectoral patenting trends, we find that U.S. patent production declines in sectors facing greater import competition. This …

HPV vaccination rates while keeping innovation incentives. We estimate the global patent buyout price as the present … to fight the disease. However, high vaccine prices enforced through patent protection are limiting vaccine expansion …, particularly in low- and middle-income countries. By limiting market power, patent buyouts could reduce vaccine prices and raise …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

surveys empirical evidence on medical R&D incentives, R&D costs of pharmaceuticals, and the cost-effectiveness of health …

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer …

generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …. -- pharmaceuticals ; pharmacies ; generic substitution …

-sample of off-patent products. First, we construct a vertical differentiation model to analyze the impact of regulation on … several off-patent molecules before and after the policy reform. Off-patent drugs not subject to RP serve as our control group …-savings, and that patients' copayments decrease despite the extra surcharges under RP. -- pharmaceuticals ; regulation ; generic …